Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioInvent Banks $116m As NHL Drug Nears Phase III

Swedish Biotech Attracting International Investors

Executive Summary

Following positive interim results from a Phase I/IIa trial of BI-1206 in combination with Roche's Rituxan, BioInvent has raised a significant sum to push the non-Hodgkin's lymphoma drug towards late-stage development.

You may also be interested in...



Fundraising Tips From The Top Of European Biotech

The biotech sector is awash with capital and the rise of the virtual roadshow is breaking down geographic barriers, giving European firms a better chance to impress US investors.

Cantargia Confident About Nadunolimab’s Prospects For Pancreatic Cancer

The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.

Sanofi Bags EU Approvals But Fumes At Regulator

Although Nexviadyme has been approved, the French group is still unhappy about the EMA's view that the Pompe disease therapy should not be classified as a new active substance.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC143878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel